These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24565713)

  • 1. Effects of mometasone, fluticasone, and montelukast on bone mineral density in adults with asthma.
    Maspero J; Backer V; Yao R; Staudinger H; Teper A
    J Allergy Clin Immunol Pract; 2013; 1(6):649-55.e1. PubMed ID: 24565713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
    O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN
    Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler.
    Zetterström O; Dahl R; Lindqvist A; Olsson P
    Respir Med; 2008 Oct; 102(10):1406-11. PubMed ID: 18640826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
    D'Urzo A; Karpel JP; Busse WW; Boulet LP; Monahan ME; Lutsky B; Staudinger H
    Curr Med Res Opin; 2005 Aug; 21(8):1281-9. PubMed ID: 16083538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential effects of fluticasone propionate on bone mineral density in patients with asthma: a 2-year randomized, double-blind, placebo-controlled trial.
    Kemp JP; Osur S; Shrewsbury SB; Herje NE; Duke SP; Harding SM; Faulkner K; Crim CC
    Mayo Clin Proc; 2004 Apr; 79(4):458-66. PubMed ID: 15065610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study.
    Maspero J; Guerra F; Cuevas F; Gutierrez JP; Soto-Ramos M; Anderton S; Mechali D; Chan R; Pedersen S
    Clin Ther; 2008 Aug; 30(8):1492-504. PubMed ID: 18803991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma.
    Karpel JP; Busse WW; Noonan MJ; Monahan ME; Lutsky B; Staudinger H
    Ann Pharmacother; 2005 Dec; 39(12):1977-83. PubMed ID: 16264062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of mometasone furoate administered via a dry powder inhaler once daily in the evening on nocturnal lung function and sleep parameters in patients with moderate persistent asthma: a randomized, double-blind, placebo-controlled pilot study.
    Krouse JH; Krouse HJ; Janisse JJ
    Clin Drug Investig; 2009; 29(1):51-8. PubMed ID: 19067474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.
    Skoner DP; Meltzer EO; Milgrom H; Stryszak P; Teper A; Staudinger H
    J Asthma; 2011 Oct; 48(8):848-59. PubMed ID: 21854342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study.
    Garcia Garcia ML; Wahn U; Gilles L; Swern A; Tozzi CA; Polos P
    Pediatrics; 2005 Aug; 116(2):360-9. PubMed ID: 16061590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of asthma exacerbation, asthma-related health care utilization and costs, and adherence to controller therapy in patients with asthma receiving fluticasone propionate/salmeterol inhalation powder 100 μg/50 μg versus mometasone furoate inhalation powder.
    Hagiwara M; Delea TE; Stanford RH
    J Asthma; 2013 Apr; 50(3):287-95. PubMed ID: 23305687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate.
    Wardlaw A; Larivee P; Eller J; Cockcroft DW; Ghaly L; Harris AG
    Ann Allergy Asthma Immunol; 2004 Jul; 93(1):49-55. PubMed ID: 15281471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparison of the effects of fluticasone propionate and budesonide on clinical indices and on bone mineral density in the asthmatic patients: a one year treatment study.
    Harmanci E; Ak I; Ozdemir N; Vardareli E; Elbek O; Uçgun I
    Allergol Immunopathol (Madr); 1999; 27(6):298-303. PubMed ID: 10611554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with inhaled mometasone furoate reduces short-acting β(2) agonist claims and increases adherence compared to fluticasone propionate in asthma patients.
    Navaratnam P; Friedman HS; Urdaneta E
    Value Health; 2011; 14(2):339-46. PubMed ID: 21402302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial.
    Harnest U; Price D; Howes T; Sussman G
    J Asthma; 2008 Apr; 45(3):215-20. PubMed ID: 18415829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial.
    Rand C; Bilderback A; Schiller K; Edelman JM; Hustad CM; Zeiger RS;
    J Allergy Clin Immunol; 2007 Apr; 119(4):916-23. PubMed ID: 17349681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids.
    Bleecker ER; Bateman ED; Busse WW; Woodcock A; Frith L; House KW; Jacques L; Davis AM; Haumann B; Lötvall J
    Ann Allergy Asthma Immunol; 2012 Nov; 109(5):353-358.e4. PubMed ID: 23062392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler.
    Noonan M; Karpel JP; Bensch GW; Ramsdell JW; Webb DR; Nolop KB; Lutsky BN
    Ann Allergy Asthma Immunol; 2001 Jan; 86(1):36-43. PubMed ID: 11206236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.
    Nelson HS; Busse WW; Kerwin E; Church N; Emmett A; Rickard K; Knobil K
    J Allergy Clin Immunol; 2000 Dec; 106(6):1088-95. PubMed ID: 11112891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
    Daley-Yates PT; Deans A; Mehta R; Sousa AR
    Pulm Pharmacol Ther; 2022 Dec; 77():102171. PubMed ID: 36243386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.